Published in Clin Cancer Res on May 15, 2005
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
Mesothelin targeted cancer immunotherapy. Eur J Cancer (2007) 2.54
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 2.25
A binding domain on mesothelin for CA125/MUC16. J Biol Chem (2008) 1.61
Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther (2012) 1.47
ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms. Clin Proteomics (2016) 1.38
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis (2013) 1.27
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther (2012) 1.27
Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett (2006) 1.25
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One (2013) 1.22
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov (2015) 1.18
Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res (2005) 1.14
PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One (2014) 1.13
The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem (2013) 1.12
Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res (2009) 1.08
Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol (2009) 1.08
A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer (2011) 1.06
Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer (2010) 1.05
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med (2014) 1.04
Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Mol Cancer Ther (2014) 1.03
Immunosignaturing can detect products from molecular markers in brain cancer. PLoS One (2012) 1.01
Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med (2013) 0.94
The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res (2010) 0.92
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer (2011) 0.91
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother (2011) 0.90
A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther (2013) 0.88
Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw (2012) 0.87
Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs (2011) 0.87
Transwells with microstamped membranes produce micropatterned two-dimensional and three-dimensional co-cultures. Tissue Eng Part C Methods (2010) 0.87
HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy. J Cancer (2011) 0.86
Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother (2014) 0.84
Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights. J Biol Chem (2012) 0.84
Novel findings about management of gastric cancer: a summary from 10th IGCC. World J Gastroenterol (2014) 0.84
Near infrared photoimmunotherapy with an anti-mesothelin antibody. Oncotarget (2016) 0.84
Retracted Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev (2015) 0.84
What is recent in pancreatic cancer immunotherapy? Biomed Res Int (2012) 0.84
Malignant Mesothelioma Effusions Are Infiltrated by CD3(+) T Cells Highly Expressing PD-L1 and the PD-L1(+) Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. J Thorac Oncol (2016) 0.84
Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors. Mol Cancer Ther (2015) 0.83
New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma. Sci Rep (2015) 0.81
Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. MAbs (2014) 0.81
Linking the ovarian cancer transcriptome and immunome. BMC Syst Biol (2008) 0.81
Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. Cancer Res (2015) 0.81
Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line. PLoS One (2015) 0.80
The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma. Oncol Lett (2012) 0.80
The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors. J Ovarian Res (2011) 0.80
A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas. J Histochem Cytochem (2012) 0.79
Autoantibodies as biomarkers for ovarian cancer. Cancer Biomark (2011) 0.79
Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology. Sci Rep (2016) 0.79
Autoantibodies to mesothelin in infertility. Cancer Epidemiol Biomarkers Prev (2011) 0.78
Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice. PLoS One (2013) 0.78
What's the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr (2010) 0.78
Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.78
Ovarian cancer stroma: pathophysiology and the roles in cancer development. Cancers (Basel) (2012) 0.77
Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. Oncotarget (2016) 0.77
Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. Sci Rep (2016) 0.77
Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy. PLoS One (2015) 0.77
Anti-HE4 antibodies in infertile women and women with ovarian cancer. Gynecol Oncol (2013) 0.76
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. Mol Cancer Ther (2016) 0.76
Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts. BMC Cancer (2013) 0.75
Investigational approaches for mesothelioma. Front Oncol (2011) 0.75
Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes. J Pathol Transl Med (2017) 0.75
Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples. MAbs (2017) 0.75
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Mesothelin: a new target for immunotherapy. Clin Cancer Res (2004) 4.30
Immunotoxin therapy of cancer. Nat Rev Cancer (2006) 3.93
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol (2012) 2.58
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Immunotoxin treatment of cancer. Annu Rev Med (2007) 2.36
Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol (2005) 2.33
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res (2002) 2.30
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res (2009) 2.17
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol (2012) 2.15
Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria. Kidney Int (2008) 2.14
Mesothelin expression in human lung cancer. Clin Cancer Res (2007) 2.10
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun (2007) 2.00
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res (2006) 1.99
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol (2009) 1.86
Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol (2005) 1.84
Distinct roles of segregated transmission of the septo-habenular pathway in anxiety and fear. Neuron (2013) 1.78
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res (2011) 1.78
Podocyte injury damages other podocytes. J Am Soc Nephrol (2011) 1.75
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery (2007) 1.74
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood (2008) 1.74
Patch-clamp studies in the CNS illustrate a simple new method for obtaining viable neurons in rat brain slices: glycerol replacement of NaCl protects CNS neurons. J Neurosci Methods (2006) 1.72
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res (2008) 1.71
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J (2011) 1.70
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A (2008) 1.66
Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res (2004) 1.65
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res (2010) 1.64
A binding domain on mesothelin for CA125/MUC16. J Biol Chem (2008) 1.61
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res (2010) 1.59
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res (2006) 1.57
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem (2004) 1.54
Mice are unable to endogenously regenerate podocytes during the repair of immunotoxin-induced glomerular injury. Nephrol Dial Transplant (2013) 1.54
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res (2011) 1.54
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol (2007) 1.52
Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther (2012) 1.47
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res (2007) 1.47
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A (2012) 1.44
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A (2012) 1.42
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A (2007) 1.41
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol (2007) 1.39
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res (2005) 1.39
Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc Natl Acad Sci U S A (2003) 1.39
Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci U S A (2006) 1.37
Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res (2008) 1.34
Immunotoxins for leukemia. Blood (2014) 1.33
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res (2005) 1.32
Multilayered specification of the T-cell lineage fate. Immunol Rev (2010) 1.32
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci U S A (2006) 1.30
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One (2012) 1.30
Presynaptic glycine receptors on GABAergic terminals facilitate discharge of dopaminergic neurons in ventral tegmental area. J Neurosci (2004) 1.29
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A (2011) 1.29
Permanent genetic tagging of podocytes: fate of injured podocytes in a mouse model of glomerular sclerosis. J Am Soc Nephrol (2005) 1.28
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther (2012) 1.27
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res (2007) 1.27
Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function. J Neurosci (2003) 1.27
POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta, and prostate cancer. Proc Natl Acad Sci U S A (2002) 1.25
NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. Proc Natl Acad Sci U S A (2004) 1.25
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res (2011) 1.25
Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev (2006) 1.24
Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cell Biol (2010) 1.23
Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. Proc Natl Acad Sci U S A (2003) 1.22
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res (2010) 1.21